Abnormal methylation of NCAPH2 in the blood of patients with subjective cognitive decline may be a biomarker for early screening of Alzheimer’s disease [17], but no related research has mentioned that NCAPH2 was related to cancer prognosis. This evidence concerns the gene NCAPH2 and cancer.